1. Home
  2. NAMSW vs BTE Comparison

NAMSW vs BTE Comparison

Compare NAMSW & BTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • BTE
  • Stock Information
  • Founded
  • NAMSW N/A
  • BTE 1993
  • Country
  • NAMSW Netherlands
  • BTE Canada
  • Employees
  • NAMSW 29
  • BTE N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • BTE Meat/Poultry/Fish
  • Sector
  • NAMSW Health Care
  • BTE Consumer Staples
  • Exchange
  • NAMSW Nasdaq
  • BTE Nasdaq
  • Market Cap
  • NAMSW N/A
  • BTE N/A
  • IPO Year
  • NAMSW N/A
  • BTE N/A
  • Fundamental
  • Price
  • NAMSW $9.00
  • BTE $3.69
  • Analyst Decision
  • NAMSW
  • BTE
  • Analyst Count
  • NAMSW 0
  • BTE 0
  • Target Price
  • NAMSW N/A
  • BTE N/A
  • AVG Volume (30 Days)
  • NAMSW N/A
  • BTE 8.9M
  • Earning Date
  • NAMSW N/A
  • BTE 07-25-2024
  • Dividend Yield
  • NAMSW N/A
  • BTE 1.77%
  • EPS Growth
  • NAMSW N/A
  • BTE N/A
  • EPS
  • NAMSW N/A
  • BTE N/A
  • Revenue
  • NAMSW N/A
  • BTE $2,224,828,676.00
  • Revenue This Year
  • NAMSW N/A
  • BTE $42.77
  • Revenue Next Year
  • NAMSW N/A
  • BTE $4.44
  • P/E Ratio
  • NAMSW N/A
  • BTE N/A
  • Revenue Growth
  • NAMSW N/A
  • BTE 35.26
  • 52 Week Low
  • NAMSW N/A
  • BTE $2.92
  • 52 Week High
  • NAMSW N/A
  • BTE $4.65
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 47.48
  • BTE 56.00
  • Support Level
  • NAMSW $8.35
  • BTE $3.59
  • Resistance Level
  • NAMSW $10.14
  • BTE $3.84
  • Average True Range (ATR)
  • NAMSW 0.33
  • BTE 0.11
  • MACD
  • NAMSW -0.12
  • BTE 0.01
  • Stochastic Oscillator
  • NAMSW 22.97
  • BTE 52.97

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: